Список проголосовавших за комментарий "<table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">ArQule and Daiichi Sankyo (DSNKY) announce the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma did not meet its primary endpoint of improving overall survival (1.47)<p>Full results from the trial will be presented at an upcoming scientific forum.</p><p><em>ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET</em></p></td> </tr></table>"